ClinicalTrials.gg
CompletedNCT04574284Updated May 28, 2025

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

A Phase 2 interventional study of TQB2450 and Anlotinib in Advanced Endometrial Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 36 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 170 studies in Endometrial Neoplasms with a site in China — 98 open to participants now, 120 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Enrollment
57th of 140
170 · median 115
Started
2020
with 14 others
Phase 2
41 of 170
29 open now
Registered
36th of 170
by date
Lead sponsor
4 of 170
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 170 studies in Endometrial Neoplasms with a site in China, this one is the 57th largest by enrollment of the 140 interventional ones that give a count, is one of 15 that started in 2020, is one of 41 in phase 2, and was the 36th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 471 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

98 of the 170 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 357 Endometrial Neoplasms studies recruiting now, 267 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 170 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer.

03

Conditions studied

  • Advanced Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Understood and signed an form. 2. (ECOG) performance status of 0 to 1; ≥ 3 months.

      1. Histopathologically confirmed recurrent or advanced endometrial cancer.
      1. Has at least one . 5. Agree to provide tumor tissue samples for MSI/MMR status detection. 6. Adequate laboratory indicators. 7. Serum or urine pregnancy tests are negative within 7 days before randomization; Men and women should agree to use effective during the study period and after the end of the study period within 6 months.

Exclusion criteria

Exclusion Criteria:

  • 1.Concomitant disease and medical history:

    1. Has diagnosed and/or treated additional within 3 years prior to randomization;
    2. Pathological diagnosed as uterine sarcoma;
    3. Has multiple factors affecting oral medication;
    4. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy.
    5. Has received major surgical treatment, open and so on within 28 days before the start of the study.
    6. Has a unhealed wound or fracture for a long time;
    7. Has cerebrovascular accident, deep vein thrombosis and pulmonary embolism within 6 months before the study;
    8. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures;
    9. Has a history of psychotropic substance abuse and unable to quit or mental disorders;
    10. Has any serious and / or uncontrolled disease; 2. Tumor-related symptoms and treatment:

    <!-- -->

    1. Has received surgery, chemotherapy, radiotherapy or other anticancer therapy within 4 weeks before the start of the study;
    2. Has received proprietary Chinese medicine with anti-tumor indications in the NMPA approved drug instructions within 2 weeks before the start of the study;
    3. Has received immunotherapeutic drugs against , PD-L1, CTLA-4 and other related drugs;
    4. Has used antiangiogenic drugs such as bevacizumab, anlotinib, apatinib, lenvatinib, sorafenib, Sunitinib, regorafenib, fruquintinib, etc;
    5. Has received hormone therapy for endometrial cancer within a week before the first dose ;
    6. CT or MRI showed that the tumor had invaded the important blood vessels;
    7. Has symptomatic central nervous system (CNS) disease and/or cancerous meningitis, pia mater disease; 3. Related to research and treatment:

    <!-- -->

    1. Has received attenuated within 28 days before randomization or planned to received attenuated live vaccine during the study period.
    2. Has a history of severe allergic diseases.
    3. Has active diseases requiring systemic treatment occurred within 2 years before the study.

      1. Has Participated in other clinical trials within 4 weeks before first dose. 5. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    TQB2450 + Anlotinib

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 · Drug: Anlotinib

  • Experimental
    TQB2450

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.

    Drug: TQB2450

  • Experimental
    Anlotinib

    Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: Anlotinib

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • A multi-target receptor tyrosine kinase inhibitor.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) evaluated by Independent Review Committee(IRC)

    ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on IRC.

    Time frame: up to 12 months

Secondary outcomes

  1. Overall response rate (ORR) evaluated by investigator

    ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.

    Time frame: up to 12 months

  2. Disease control rate (DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 12 months

  3. Duration of response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 12 months

  4. Progression free survival(PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 12 months

  5. Overall survival(OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 18 months

  6. DOR rate (≥ 6 months)

    The percentage of participants achieved complete or partial remission ≥ 6 months.

    Time frame: up to 6 months

07

Study locations

36 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing 100016, China
  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University
    Beijing, Beijing 100016, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital
    Beijing, Beijing 101100, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, Beijing 101149, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Gansu Province Maternity and Chid-care Hospital
    Lanzhou, Gansu 730050, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510080, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510289, China
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530022, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071002, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 4500003, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210009, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110041, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong 256600, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276034, China
  • Qingdao Central Hospital
    Qingdao, Shandong 266042, China
  • Weifang People's Hospital
    Weifang, Shandong 261000, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Obstetrics & Gynecology Hospital of Fudan University
    Shanghai, Shanghai 200090, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • Xi'an People's Hospital
    Xi'an, Shanxi 710004, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
  • Tianjin Central Hospital of Gynecology Obstetrics
    Tianjin, Tianjin 300052, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300060, China
  • First Affiliated Hospital, School of Medicine, Shihezi University
    Shihezi, Xinjiang Uygur Autonomous Region 832008, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang Uygur Autonomous Region 830000, China
  • Xinjiang Medical University Affiliated Tumor Hospital
    Urumqi, Xinjiang Uygur Autonomous Region 830000, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Nov 2023, 37 months.

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 5, 2020
StartActual
Sep 29, 2020
Primary completionActual
Nov 9, 2023
CompletionActual
May 9, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04574284
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Sep 29, 2020
Primary completion
Nov 9, 2023
Completion
May 9, 2024
Last update
May 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion